- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
PM chairs Task Force meeting on Corona Vaccine Development, Drug Discovery, Diagnosis and Testing
In diagnosis and testing, several academic research institutions and start-ups have developed new tests, both for the RT-PCR approach and for antibody detection
New Delhi: The PM took a detailed review of the current status of India's efforts in vaccine development, drug discovery, diagnosis and testing. Indian vaccine companies are well known for their quality, manufacturing capacity and global presence. Today, in addition, they have come across as innovators in early-stage vaccine development research. Similarly, Indian academia and start-ups have also pioneered in this area. Over 30 Indian vaccines are in different stages of corona vaccine development, with a few going on to the trial stages.
Similarly, in drug development, three approaches are being taken. First, the repurposing of existing drugs. At least four drugs are undergoing synthesis and examination in this category. Secondly, the development of new candidate drugs and molecules are being driven by linking high performance computational approached with laboratory verification. Thirdly, plant extracts and products are being examined for general anti-viral properties.
In diagnosis and testing, several academic research institutions and start-ups have developed new tests, both for the RT-PCR approach and for antibody detection. In addition, by linking laboratories all over the country, capacity for both these kinds of tests have been enormously scaled up. The problem of importing reagents for testing has been addressed by consortia of Indian start-ups and industry, meeting current requirements. The current thrust also holds promise for the development of a robust long-term industry in this area.
The review by the PM took note of the extraordinary coming together of academia, industry and government, combined with the speedy but efficient regulatory process. The PM desired that such coordination and speed should be embedded into a standard operating procedure. He emphasized that what is possible in a crisis should be a part of our routine way of scientific functioning.
Appreciating the scientific coming together of computer science, chemistry and biotechnology in drug discovery, the PM suggested that a hackathon be held on this subject, linking computer science to synthesis and testing in the laboratory. The successful candidates from the hackathon could be taken up by the start-ups for further development and scaling up.
The PM added that the innovative and original manner in which Indian scientists, from basic to applied sciences, have come together with industry is heartening. This kind of pride, originality and sense of purpose should dominate our approach going ahead. It is only then that we can be amongst the best in the world and not followers, in science.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751